Zolendronic Acid

# Zolendronic acid ## Overview - **Classification**: Bisphosphonate - **Mechanism**: Inhibits osteoclast activity by binding to bone hydroxyapatite, reducing bone resorption and turnover. ## Primary Indications 1. **Hypercalcemia of Malignancy (HCM)** - Acute reduction of elevated serum calcium levels. 2. **Multiple Myeloma & Bone Metastases of Solid Tumors** - Prevention of skeletal-related events (SREs). 3. **Osteoporosis (Postmenopausal, Male, Glucocorticoid-induced)** - Treatment and prevention of bone loss. 4. **Paget's Disease of Bone** - Treatment of moderate to severe Paget's disease. ## Adult Dosing ### Standard Dosing **Hypercalcemia of Malignancy (HCM)** - **Dose**: **4 mg** - **Frequency**: Single IV infusion; may repeat after ≥7 days if needed. - **Route**: IV infusion over at least **15 minutes**. - **Special Considerations**: Ensure adequate hydration before and during administration. **Multiple Myeloma & Bone Metastases of Solid Tumors** - **Dose**: **4 mg** - **Frequency**: Every **3-4 weeks**. - **Route**: IV infusion over at least **15 minutes**. - **Special Considerations**: Co-administer calcium **500 mg** and vitamin D **400 IU** daily. **Osteoporosis (Postmenopausal, Male, Glucocorticoid-induced)** - **Dose**: **5 mg** - **Frequency**: Once every **12 months**. - **Route**: IV infusion over at least **15 minutes**. - **Duration**: Typically 3-5 years; reassess thereafter. **Paget's Disease of Bone** - **Dose**: **5 mg** - **Frequency**: Single IV infusion. - **Route**: IV infusion over at least **15 minutes**. - **Special Considerations**: Consider retreat if relapse occurs after ≥12 months. ### Dose Adjustments - **Renal Impairment**: - **CrCl >60 mL/min**: No adjustment. - **CrCl 30-60 mL/min**: - **HCM**: **4 mg** infusion over **30 minutes**. - **Other indications**: **Contraindicated** for osteoporosis/Paget's or prevention of SREs. - **CrCl <30 mL/min**: **Contraindicated** for all indications due to increased risk of renal toxicity. - **Hepatic Impairment**: No dose adjustment required. - **Elderly Patients**: No specific dose adjustment; monitor renal function closely. ## Pediatric Dosing *Zolendronic acid is generally **not recommended** for routine use in pediatric patients outside of specific conditions like severe osteogenesis imperfecta or hypercalcemia of malignancy, and only under specialist guidance.* **Note**: Limited data for most pediatric indications. Use only under expert supervision. ### Neonates (0-28 days) - **Use**: Generally **not recommended**. - **Special Notes**: Extremely limited data, high risk of hypocalcemia/renal issues. ### Infants (1-12 months) - **Use**: Generally **not recommended** for routine use. - **Severe Osteogenesis Imperfecta (off-label, rare)**: **0.025 mg/kg** IV infusion every 3-4 weeks. - **Maximum**: **0.05 mg/kg/dose**. - **Special Notes**: Requires careful monitoring for hypocalcemia. ### Children (1-12 years) - **Use**: Generally **not recommended** for routine use. - **Severe Osteogenesis Imperfecta (off-label)**: **0.025-0.05 mg/kg** IV infusion every 3-6 months. - **Maximum**: **4 mg** per dose. - **Hypercalcemia of Malignancy (off-label)**: **0.025-0.05 mg/kg** IV (max **4 mg**). ### Adolescents (13-18 years) - **Hypercalcemia of Malignancy (off-label)**: Dose similar to adults, **4 mg** IV over 15 min. - **Severe Osteogenesis Imperfecta (off-label)**: **0.05 mg/kg** IV every 3-6 months (max **4 mg**). - **Maximum**: **4 mg** for oncology; **5 mg** for osteoporosis/Paget's (if indicated and after epiphyseal closure). - **Special Notes**: Consider epiphyseal closure status for long-term use. ## Safety Information ### Contraindications - **Absolute**: Hypocalcemia. - **Absolute**: Severe renal impairment (CrCl <30 mL/min for all indications, CrCl <60 mL/min for osteoporosis/Paget's). - **Absolute**: Pregnancy and lactation. - **Absolute**: Hypersensitivity to zolendronic acid or other bisphosphonates. ### Common Adverse Effects - **Very Common (>10%)**: Flu-like symptoms (fever, myalgia, arthralgia, headache), fatigue. - **Common (1-10%)**: Nausea, vomiting, diarrhea, constipation, anemia, hypophosphatemia. - **Serious but Rare**: Osteonecrosis of the jaw (ONJ), atypical femoral fractures, renal impairment, ocular inflammation, atrial fibrillation. ### Key Drug Interactions - **Aminoglycosides/Loop Diuretics**: Increased risk of hypocalcemia. - **Nephrotoxic Drugs**: Increased risk of renal toxicity when co-administered. - **Thalidomide/Dexamethasone**: No direct interaction, but part of complex regimens in multiple myeloma. ## Monitoring & Follow-up - **Before Treatment**: - Serum creatinine, calcium, phosphate, magnesium. - Dental exam (especially for oncology patients). - **During Treatment**: - Serum creatinine (before each dose for oncology indications). - Serum electrolytes (calcium, phosphate, magnesium) for hypocalcemia risk. - Monitor for signs/symptoms of ONJ or atypical femoral fracture. - **Clinical Signs**: - Bone pain, swelling in jaw, non-healing oral lesions. - New or unusual thigh/groin pain. - Signs of hypocalcemia (e.g., muscle cramps, numbness/tingling). ## Clinical Pearls - 💡 **Hydration**: Ensure adequate hydration before each infusion to reduce the risk of renal toxicity. - 💡 **Calcium/Vit D**: Supplement with oral calcium and vitamin D daily, especially for osteoporosis and bone metastases. - 💡 **Dental Care**: Counsel patients on good oral hygiene and to report any jaw pain or non-healing oral lesions immediately. - 💡 **Infusion Rate**: Infuse slowly over at least **15 minutes** (or 30 min for specific renal impairment in HCM) to prevent renal events. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.